Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 216 clinical trials
Isatuximab in Combination With Lenalidomide and Dexamethasone in High-risk Smoldering Multiple Myeloma

Primary Objectives:

<ul>
  • Safety run-in: To confirm the recommended dose of isatuximab when combined with lenalidomide and dexamethasone in participants with high-risk smoldering multiple myeloma (SMM)
  • Randomized Phase 3: To demonstrate the clinical benefit of isatuximab in combination with lenalidomide and dexamethasone in the prolongation of progression-free survival when …

    dexamethasone
    bone marrow plasma cells
    bone marrow procedure
    lenalidomide
    isatuximab
    • 0 views
    • 19 Feb, 2024
    • 16 locations
    Isatuximab in Combination With Lenalidomide and Dexamethasone in High-risk Smoldering Multiple Myeloma

    Primary Objectives:

    <ul>
  • Safety run-in: To confirm the recommended dose of isatuximab when combined with lenalidomide and dexamethasone in participants with high-risk smoldering multiple myeloma (SMM)
  • Randomized Phase 3: To demonstrate the clinical benefit of isatuximab in combination with lenalidomide and dexamethasone in the prolongation of progression-free survival when compared …

    dexamethasone
    bone marrow plasma cells
    bone marrow procedure
    lenalidomide
    isatuximab
    • 0 views
    • 19 Feb, 2024
    • 11 locations
    Systematic Evaluation of Ablation Techniques for Non-Paroxysmal Atrial Fibrillation.

    The purpose of this study is to evaluate the safety and effectiveness of empirical posterior wall isolation (PWI), left atrial appendage electrical isolation (LAAEI) and coronary sinus isolation (CSI) when compared to pulmonary vein isolation (PVI) alone:

    <ul>
  • PVI alone,
  • PVI + PWI,
  • PVI + PWI + LAAEI,
  • PVI …

    left ventricular dysfunction
    paroxysmal atrial fibrillation
    chest pain
    pulmonary vein isolation
    dyspnea
    • 0 views
    • 19 Feb, 2024
    Long-term Safety and Efficacy Study of Fitusiran in Patients With Hemophilia A or B With or Without Inhibitory Antibodies to Factor VIII or IX

    Primary Objective:

    To characterize the long-term safety and tolerability of fitusiran

    Secondary Objectives:

    <ul>
  • To characterize the long-term efficacy of fitusiran as assessed by the frequency of:
  • Bleeding episodes
  • Spontaneous bleeding episodes
  • Target joint bleeding episodes
  • To characterize the effects of fitusiran on health-related quality of life (HRQOL) …

    hemarthrosis
    antihemophilic factor
    hemophilia
    fitusiran
    haemophilia a
    • 0 views
    • 19 Feb, 2024
    • 41 locations
    SAR408701 Versus Docetaxel in Previously Treated Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Positive Metastatic Non-squamous Non-small Cell Lung Cancer Patients

  • The primary objective is to determine whether SAR408701 improves the overall survival (OS) when compared with docetaxel in participants with metastatic non-squamous NSCLC expressing CEACAM5 2+ in intensity in at least 50% of the tumor cell population and previously treated with standard-of-care platinum-based chemotherapy and an immune checkpoint inhibitor.
    • ul>

    …

    platinum-based chemotherapy
    measurable disease
    lung cancer
    non-squamous non-small cell lung cancer
    stage iv non-small cell lung cancer
    • 0 views
    • 19 Feb, 2024
    • 169 locations
    Study of a Pneumococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Toddlers and Infants  

    Primary Objective:

    <ul>
  • To assess the safety profile of each SP0202 formulation and Prevnar 13 in toddlers and infants (after each and any injection).

    • 0 views
    • 19 Feb, 2024
    • 31 locations
    Study on a High-Dose Quadrivalent Influenza Vaccine Compared With Standard-Dose Quadrivalent Influenza Vaccine in Children 6 Months Through 35 Months of Age

  • To compare hemagglutination inhibition (HAI) immune response of QIV-HD to QIV-SD in participants 6 months through 35 months of age
  • To describe the HAI, seroneutralization (SN), and anti-neuraminidase (NA) immune response
  • To describe the immune response to revaccination in Season 3 (Northern Hemisphere)
  • To describe the safety profile of each …

    vaccination
    hemagglutination inhibition
    influenza
    quadrivalent inactivated influenza vaccine
    flu symptoms
    • 0 views
    • 19 Feb, 2024
    • 9 locations
    Immunogenicity and Safety Study of a Quadrivalent Meningococcal Conjugate Vaccine When Co-administered With Routine Pediatric Vaccines in Healthy Infants and Toddlers in Europe

  • To describe the safety profile of MenACYW conjugate vaccine and a licensed meningococcal vaccine.
    • ul>

    antibody response
    antibiotics
    meningococcal vaccine
    meningococcal conjugate
    pneumococcal
    • 0 views
    • 19 Feb, 2024
    • 29 locations
    Immunogenicity and Safety Study of a Quadrivalent Meningococcal Conjugate Vaccine When Co-administered With Routine Pediatric Vaccines in Healthy Infants and Toddlers in Europe

  • To describe the safety profile of MenACYW conjugate vaccine and a licensed meningococcal vaccine.
    • ul>

    antibody response
    antibiotics
    meningococcal vaccine
    meningococcal conjugate
    pneumococcal
    • 0 views
    • 19 Feb, 2024
    • 29 locations
    Asian Diabetes Outcomes Prevention Trial

    The aim of this study is to identify patients with DM at high risk of CVD using elevated N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels (>125pg/mL), and (2) intensify therapy using renin-angiotensin system (RAS) antagonists, beta-blockers and sodium glucose co-transporter-2 inhibitors (SGLT2i) for primary prevention of cardiovascular events in this high-risk …

    coronary artery stenosis
    amputation of the lower limb
    stenosis
    infarct
    heart failure
    • 0 views
    • 19 Feb, 2024